Proteomics makes blood test breakthrough for deadly throat cancer – The Sydney Morning Herald
ASX-listed diagnostics pioneer Proteomics International Laboratories has revealed a set of stunning clinical results for its simple PromarkerEso blood test for throat cancer, paving the way for the innovative test to be commercially released.
The findings have delivered a genuine medical game-changer. Proteomics says its PromarkerEso test has been shown to detect early stages of esophageal adenocarcinoma (EAC) with extraordinary accuracy. The study involved 350 participants across two independent trials and delivered a near-perfect score with a minimum area under the curve measure of 0.97 across all cancer stages.
